Marek Atter

Research Fellow in Health Economics

Background

Marek is a health economist mainly working on economic analyses & models for clinical trials for the Edinburgh Clinical Trials Unit (ECTU). 
He is also involved with MyPath, which is an upcoming digital intervention in Patient-Centred care (including e.g. symptom tracking & ePROMs) and will be responsible for modelling its economic impact.

Research summary

  1.     Atter M, Stoddart A, Vadiveloo T, et al. The ALLEGRO trial, A placebo controlled rAndomised trial of intravenous Lidocaine in acceLErating Gastrointestinal Recovery after cOlorectal surgery: Health Economic Evaluation [Unpublished manuscript] 2024.
  2.     Henriksen PA, Maclean M, Atter M, Lewis S, Rodriguez A. High-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE RCT [Unpublished manuscript] 2022.
  3.     Cresswell K, Anderson S, Montgomery C, Weir CJ, Atter M, Williams R. Evaluation of Digitalisation in Healthcare and the Quantification of the “Unmeasurable.” J Gen Intern Med. 2023;38(16):3610-3615. doi:10.1007/s11606-023-08405-y
  4.     Paterson H, Vadiveloo T, Innes K, et al. The ALLEGRO trial: A placebo controlled rAndomised trial of intravenous Lidocaine in acceLErating Gastrointestinal Recovery after cOlorectal surgery [Unpublished manuscript] 2024.

Affiliated research centres

Project activity

MyPath is a project funded European Union (grant no. 101057514) and supported by Innovate UK and the Swiss State Secretariat for Education, Research and Innovation (SERI) with the ambition of establishing integrated and efficient patient-centred care that is respectful of, and responsive to, individual patient preferences, needs, and values.

Marek is responsible for:

  • Providing specialist health economics advice
  • Designing and advising on health economic data collection
  • Designing a health economic model capable of evaluating a complex digital intervention